Table 3.

Cumulative incidence of molecular responses by transcript types in patients treated with imatinib.

Reference	CI4MMR5					CI4DMR6
	E13a2 %	E14a2 %	E13a2+e14a2 %	p-value	Follow-up	E13a2 %	E14a2 %	E13a2+e14a2 %	p-value	Follow-up
Hanfstein et al. (23)	81	85	NR1	0.002	5 y3	58	76	NR1	<0.001	5 y3
Sharma et al. (31)	NR1	NR1	NR1	NR1	NR1	NR1	NR1	NR1	NR1	NR1
Jain et al. (24)	79	91	95	0.0001	5 y3	57	79	80	<0.001	5 y3
Castagnetti et al. (25)	83	88	NR1	<0.01	80 mo2	52	67	NR1	0.001	80 mo2
Pagnano et al. (28)	NR1	NR1	NR1	NR10	NR1	NR1	NR1	NR1	NR1	NR1
Vega - Ruiz et al. (30)	59	77	NR1	0.008	62mo2	25	47	NR1	0.002	62mo2
Polampalli et al. (69)	NR1	NR1	NR1	NR1	NR1	NR1	NR1	NR1	NR1	NR1
Mir et al. (26)	64	72.1	NR1	0.04	NR1	NR1	NR1	NR1	NR1	NR1
Lin et al. (27)	60.7	77.1	81.8	<0.05	2 y3	NR1	NR1	NR1	NR1	NR1

NR= not reported; mo= months; y=years; CI= cumulative incidence; MMR= major molecular response; DMR= deep molecular response.